Quantcast

Industry news that matters to you.  Learn more

Archives for July 2010

Roche Obtains Co-Exclusive License to Develop PCR Assays Detecting Mutations in the PI3K Oncogene

Roche announced today that the company has obtained a worldwide co-exclusive license for the biomarker PI3K (phosphoinositide 3-kinase) from QIAGEN to develop real-time and endpoint PCR diagnostic assays. Johns Hopkins University owns the patent for the PI3K biomarker and has previously granted an exclusive license to QIAGEN’s wholly owned subsidiary DxS, now QIAGEN Manchester. Financial details were not disclosed.

New UC Davis Study Finds Early Alzheimer’s Identification Method

Abnormal brain images combined with examination of the composition of the fluid that surrounds the spine may offer the earliest signs identifying healthy older adults at risk of developing Alzheimer’s disease, well before cognitive problems emerge, a study by researchers at UC Davis has found.

ART-funded Researchers Find Biomarker Associated with Alzheimer’s

Research led by the Institute of Psychiatry (IoP) King’s College London (KCL) and part-funded by the Alzheimer’s Research Trust has found that certain protein levels in blood could be an early marker of Alzheimer’s.

The international team of scientists also found that higher levels of the protein, called clusterin, were related to more severe and rapid memory loss and greater brain shrinkage. Their findings could lead to development of a blood test to help identify who would benefit from early treatment for Alzheimer’s and also whether treatments were working to delay or prevent brain damage.

CROs Join with MJFF for Parkinson’s Biomarker Research

Covance, Parexel and Epitomics are working with the Michael J Fox Foundation for Parkinson’s Research (MJFF) to develop biomarker candidates.

Initiation of the projects is part of efforts by MJFF to progress biomarker research. MJFF said there is “urgent need for an orchestrated, fieldwide strategy to drive tangible progress” in the sector and contract research organisations (CRO) have a role to play in this initiative.

Michael J. Fox Foundation Announces $1.1 Million to Advance Leading Biomarker Candidates for Parkinson’s Disease

The Michael J. Fox Foundation for Parkinson’s Research today announced nearly $1.1 million for projects aimed at advancing the development of leading biomarker candidates for Parkinson’s disease. The discovery and validation of biomarkers is of critical importance to increasing the speed and efficiency of PD therapeutic development, allowing scientists and clinicians to more accurately identify appropriate subjects for clinical studies, measure disease progression and monitor treatment effects in clinical trials.